# iDose TR

Type: Product

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/idose-tr
Canonical HTML page: https://getbiobrief.com/entity/idose-tr

## Recent coverage (1 stories)

### Glaukos Surges on iDose TR Commercial Momentum in Q4 2025 Earnings
2026-02-21 07:49:50 · Sentiment: Neutral · Impact: 5/10 · Sources: 5

Glaukos Corporation reported strong Q4 2025 results, driven by the rapid commercial adoption of its iDose TR sustained-release implant and a resilient MIGS franchise. The company's strategic shift toward dropless glaucoma therapies is yielding significant revenue growth and improved 2026 guidance.
Full story: https://getbiobrief.com/story/glaukos-q4-2025-earnings-idose-tr-growth

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.